Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety, tolerability, PK and efficacy of multiple doses of ARO-ENaC in patients with pulmonary cystic fibrosis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04375514
Study type Interventional
Source Arrowhead Pharmaceuticals
Contact
Status Terminated
Phase Phase 1
Start date August 10, 2020
Completion date September 3, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05604495 - Screening for Cystic Fibrosis and Cystic Fibrosis Related Disorders in Chinese Adults With Bronchiectasis
Not yet recruiting NCT06339450 - Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects N/A
Active, not recruiting NCT06084468 - Cardiac Structure and Function in Patients With Cystic Fibrosis
Completed NCT03437811 - Airway Clearance System (K031876) Phase IV Device Efficacy